Fig 1.
Preparation scheme of the IgG-enriched plasma fraction.
Table 1.
Properties and specifications (or range) of the IgG-enriched plasma fraction.
Fig 2.
A: Patterns of 5 consecutive batches of minipool IgG-enriched plasma fractions (Minipool IgG batches B1 to B5) and control IgG (C) showing the separation between albumin (Alb) and alpha-1 (α-1), alpha-2 (α-2), bêta- (β) and gamma- (γ) proteins. B: densitographic analysis showing the percentage (%) of albumin, alpha-1, alpha-2, bêta, and gamma proteins in 5 batches (B1–B5) of minipool IgG. Control: control IgG.
Fig 3.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Patterns of 10 consecutive batches of minipool IgG-enriched plasma fractions (Minipool IgG batches B1 to B10) and control IgG (C) under non-reducing (A) or reducing (B) conditions. Control: control IgG; IgG: immunoglobulin G; Alb: albumin. MW: molecular weight markers (kDa).
Table 2.
Log removal factors of HIV-1, BVDV, and PRV during caprylic acid treatment (duplicate experiments).
Table 3.
Percent increase in body weight of rats (3 groups of 7 rats) treated with saline, commercial IgG, or minipool IgG.